Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1980 Nov;18(5):829–831. doi: 10.1128/aac.18.5.829

Influence of food on absorption of erythromycin ethyl succinate.

P J Thompson, K R Burgess, G E Marlin
PMCID: PMC284098  PMID: 6969579

Abstract

Erythromycin plasma concentrations were determined in 18 subjects after a single dose (800 mg) of a new formulation of erythromycin ethyl succinate taken immediately before, immediately after, and 1 h after food. Adequate absorption occurred with all treatments, although bioavailability was best when the drug was taken before food. Absorption was delayed by food, with the highest and earliest peak plasma erythromycin levels occurring under fasting conditions.

Full text

PDF
829

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bell S. C., Hamman J. W., Grundy W. E. Micromethod for assaying serum levels of erythromycin. Appl Microbiol. 1969 Jan;17(1):88–92. doi: 10.1128/am.17.1.88-92.1969. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bell S. M. A comparison of absorption after oral administration of erythromycin estolate and erythromycin stearate. Med J Aust. 1971 Dec 18;2(25):1280–1283. doi: 10.5694/j.1326-5377.1971.tb92846.x. [DOI] [PubMed] [Google Scholar]
  3. Cooksley W. G., Powell L. W. Erythromycin jaundice: diagnosis by an in vitro challenge test. Aust N Z J Med. 1977 Jun;7(3):291–293. doi: 10.1111/j.1445-5994.1977.tb03689.x. [DOI] [PubMed] [Google Scholar]
  4. Coyne T. C., Shum S., Chun A. H., Jeansonne L., Shirkey H. C. Bioavailability of erythromycin ethylsuccinate in pediatric patients. J Clin Pharmacol. 1978 Apr;18(4):194–202. doi: 10.1002/j.1552-4604.1978.tb01593.x. [DOI] [PubMed] [Google Scholar]
  5. Crawford L. V., Roane J. Use of erythromycin ethyl succinate in allergic children. Ann Allergy. 1969 Jan;27(1):18–22. [PubMed] [Google Scholar]
  6. GRIFFITH R. S., BLACK H. R. COMPARISON OF THE BLOOD LEVELS OBTAINED AFTER SINGLE AND MULTIPLE DOSES OF ERYTHROMYCIN ESTOLATE AND ERYTHROMYCIN STEARATE. Am J Med Sci. 1964 Jan;247:69–74. doi: 10.1097/00000441-196401000-00010. [DOI] [PubMed] [Google Scholar]
  7. McDonald P. J., Mather L. E., Story M. J. Studies on absorption of a newly developed enteric-coated erythromycin base. J Clin Pharmacol. 1977 Oct;17(10 Pt 1):601–606. doi: 10.1177/009127007701701007. [DOI] [PubMed] [Google Scholar]
  8. Mårdh P. A. Human respiratory tract infections with mycoplasmas and their in vitro susceptibility to tetracyclines and some other antibiotics. Chemotherapy. 1975;21 (Suppl 1):47–57. doi: 10.1159/000221891. [DOI] [PubMed] [Google Scholar]
  9. Nicholas P. Erythromycin: clinical review I. Clinical pharmacology. N Y State J Med. 1977 Nov;77(13):2088–2094. [PubMed] [Google Scholar]
  10. Rutland J., Berend N., Marlin G. E. The influence of food on the bioavailability of new formulations of erythromycin stearate and base. Br J Clin Pharmacol. 1979 Oct;8(4):343–347. doi: 10.1111/j.1365-2125.1979.tb04716.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Welling P. G., Huang H., Hewitt P. F., Lyons L. L. Bioavailability of erythromycin stearate: influence of food and fluid volume. J Pharm Sci. 1978 Jun;67(6):764–766. doi: 10.1002/jps.2600670608. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES